• Second quarter revenues were $12.3 billion
◦ Growth Portfolio revenues were $6.6 billion, +18% (+17% Ex-FX)
• GAAP EPS was $0.64 and non-GAAP EPS was $1.46; Both figures include net impact of $(0.57)due to the Acquired IPRD charge associated with the BioNTech strategic partnership
• Raising 2025 revenue guidance to a range of ~$46.5 billion to $47.5 billion; Updating non-GAAPEPS range to $6.35 to $6.65, inclusive of an unfavorable $(0.57) per share impact from theBioNTech Acquired IPRD charge
(PRINCETON, N.J., July 31, 2025) – Bristol Myers Squibb (NYSE: BMY) today reports results for thesecond quarter of 2025.
“We are making good progress rewiring the company for long-term growth. In the second quarter,we delivered strong results across our Growth Portfolio, continued to optimize our cost structure,and added to our innovative pipeline with strategic partnerships,” said Christopher Boerner, Ph.D.,board chair and chief executive officer, Bristol Myers Squibb. “In the back half of the year, we'refocused on advancing transformational medicines and delivering on our Growth Portfolio andimportant pipeline opportunities to shape our growth trajectory."
SECOND QUARTER RESULTS
All comparisons are made versus the same period in 2024 unless otherwise stated.
• Growth Portfolio revenues of $6.6 billion increased 18%, or 17% Ex-FX. Revenue growth wasprimarily driven by our immuno-oncology (IO) portfolio, Breyanzi, Reblozyl and Camzyos, andreflects the continued strength of Cobenfy.
• Legacy Portfolio revenues of $5.7 billion decreased 14%, or 15% Ex-FX. Demand increased forEliquis, offset by expected continued generic impact across the remainder of the LegacyPortfolio, as well as the impacts from U.S. Medicare Part D redesign.
• Total revenues of $12.3 billion increased 1%, and were relatively flat Ex-FX.
◦ U.S. revenues of $8.5 billion decreased 3%.
◦ International revenues of $3.8 billion increased 10%, or 8% Ex-FX.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines thathelp patients prevail over serious diseases. We are pursuing bold science to define what's possiblefor the future of medicine and the patients we serve.
点击阅读原文了解更多详情